Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Phase 2a Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV - An Extended Safety Evaluation

This Phase 2a study involving Tenofovir Disoproxil Fumarate (TDF) will provide extended safety data for high-risk men. Secondarily, the study will assess the feasibility of conducting the trial and evaluate the preliminary effectiveness of TDF 300 mg as an HIV prevention method when taken once a day.

Study Overview

• Status: Terminated
• Conditions: HIV Infections
• Intervention / Treatment: Drug: Tenofovir Disoproxil Fumarate

Detailed Description

TDF has been selected for investigation as prophylaxis against HIV in high-risk men because of its unique pharmacologic profile. In addition to the convenience of being a once daily single tablet, TDF's safety profile is comparable to placebo among HIV infected persons, it has striking anti-HIV potency, and it has low potential for selection of resistant viruses. TDF is cleared from the body by the kidneys and is not metabolized by the liver. Therefore, TDF has limited potential to have pharmacokinetic interactions with other hepatically metabolized drugs. Each of these properties is necessary given the realities of the intended target populations. Moreover, initial prevention studies in simian models have provided encouraging results. Finally, the drug's sponsor is supportive of investigating the potential use of TDF as a preventive, as well as therapeutic agent, will provide TDF for the study, and is willing to make a good faith effort to make TDF available for public health use should it prove to be effective for HIV prevention.

• Study Type: Interventional
• Enrollment: 500
• Phase: Phase 2

Contacts and Locations

Study Locations

• Malawi
  • Lilongwe, Malawi
    • UNC Project, Kamuzu Central Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

• Be willing and able to give informed consent
• Be 18 years or older
• Be willing to use study product as directed
• Be willing to adhere to follow-up schedule
• Be willing to participate in the study for up to 12 months
• Be in general good health (no active, serious infections that require parenteral antibiotics, no active clinically significant medical conditions, including heart disease, diabetes, asthma, alcoholism, and cancer)

• Meet at least one of these three high risk criteria: *Sex with sex worker/bar girl in last 3 months;

  • Sex with 2 or more women in last 3 months;
  • Sexually transmitted disease (STD) in last 3 months
• Have absence of HIV antibodies by rapid test (at screening and enrollment visit)
• Have absence of hepatitis B (HB) surface antigen (sAg)
• Have adequate renal function (serum creatinine <1.5 mg/dL)
• Have adequate liver function (hepatic transaminases (ALT <54 U/L and AST<46 U/L)
• Have adequate serum phosphorus (>2.2 mg/dL)
• Not be intending to relocate out of the area for the duration of the study participation and does not have a job or other obligations that may require long absences from the area
• Not be receiving an experimental HIV vaccine

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To evaluate the extended safety of TDM 300mg daily among HIV-uninfected men

Secondary Outcome Measures

Outcome Measure
To evaluate the feasibility (i.e. accrual, retention, adherence, change in behavior) of conducting a large scale trial of TDF for HIV prevention in men recruited from a resource-limited setting
To assess the preliminary effectiveness of TDF in preventing HIV infection among men at high risk for HIV

Collaborators and Investigators

• Sponsor: FHI 360
• Investigators: Principal Investigator: Irving Hoffman, PA, MPH, UNC Center for Infectious Diseases

Study record dates

Study Registration Dates

• First Submitted: July 19, 2005
• First Submitted That Met QC Criteria: July 21, 2005
• First Posted (Estimate): July 22, 2005

Study Record Updates

• Last Update Posted (Estimate): February 10, 2006
• Last Update Submitted That Met QC Criteria: February 9, 2006
• Last Verified: February 1, 2006

More Information

Terms related to this study

• Keywords: HIV Seronegativity; Human Immunodeficiency Virus; AE adverse event; AIDS acquired immunodeficiency syndrome; ALT (SGPT) alanine aminotransferase; ART antiretroviral therapy; AST (SGOT) aspartate aminotransferase; DCF data collection forms; DMC Data Monitoring Committee; FDA (U.S.) Food and Drug Administration; GCP Good Clinical Practice guidelines; HB sAg Hepatitis B surface antigen; ICH International Conference of Harmonisation; IND Investigational New Drug Application; IRB Institutional Review Board; mg milligram(s); mm3 cubic millimeter(s); PCR polymerase chain reaction; SAE serious adverse event; µg microgram; ULN upper limit of the normal range; WB Western Blot; IU international units; TDF tenofovir disoproxil fumarate, GS-4331-05, PMPA prodrug
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; HIV Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Reverse Transcriptase Inhibitors; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Anti-HIV Agents; Anti-Retroviral Agents; Tenofovir
• Other Study ID Numbers: 9876 (CTEP)